[EFFECT] Galmed Pharmaceuticals Ltd. SEC Filing

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

EFFECT

04/02/2026 - 12:15 AM

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date:	April 1, 2026

Accession Number:

0001493152-26-014239

Submission Type:

POS AM

CIK:	0001595353
Company Name:	Galmed Pharmaceuticals Ltd.
File Number:	333-289703

Source: View Original Filing on SEC EDGAR

Galmed Pharmaceu

NASDAQ:GLMD

View GLMD Stock Overview →

GLMD Rankings

#6851 Ranked by Market Cap

N/A Ranked by Dividends

GLMD Latest News

Mar 31, 2026

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

Jan 30, 2026

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

Dec 8, 2025

Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting

Dec 4, 2025

Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH

Dec 1, 2025

Galmed Issues CEO Letter to Shareholders

GLMD Latest SEC Filings

Mar 31, 2026

[20-F] Galmed Pharmaceuticals Ltd. Files Annual Report (Foreign Issuer)

Mar 18, 2026

[Form 3] Galmed Pharmaceuticals Ltd. Initial Statement of Beneficial Ownership

Mar 18, 2026

[Form 3] Galmed Pharmaceuticals Ltd. Initial Statement of Beneficial Ownership

Mar 18, 2026

[Form 3] Galmed Pharmaceuticals Ltd. Initial Statement of Beneficial Ownership

Mar 18, 2026

[Form 3] Galmed Pharmaceuticals Ltd. Initial Statement of Beneficial Ownership

GLMD Stock Data

Market Cap 3.49M

Float 6.52M

Industry Biotechnology

Sector Healthcare

Website Link

Country Israel

City Ramat Gan